Suppr超能文献

COPD 的正确诊断及支气管扩张剂治疗的注意事项。

Considerations for the Correct Diagnosis of COPD and Its Management With Bronchodilators.

机构信息

Pulmonary/Critical Care, University of Texas Health Science Center and South Texas Veterans Health Care System, San Antonio, TX.

Pneumology Department, Hospital Universitario Vall d'Hebron, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain.

出版信息

Chest. 2018 Aug;154(2):242-248. doi: 10.1016/j.chest.2018.02.023. Epub 2018 Mar 8.

Abstract

COPD is often misdiagnosed and inappropriately treated in many patients. COPD is a distinct disease from adult-onset asthma; however, some patients with COPD may present with several forms of airway disease described as asthma-COPD overlap (ACO). Bronchodilators and inhaled corticosteroids (ICS) both have a place in standard maintenance treatment of COPD and asthma; however, recommendations for use differ widely. In patients with COPD, long-acting bronchodilators are effective initial monotherapy treatment, whereas ICS monotherapy is recommended as initial treatment in patients with asthma. Clinicians need to be confident in their diagnosis to ensure that correct treatment is given because misguided treatment decisions can result in significantly increased safety risks for patients. This review highlights the differences in diagnosis and treatment between COPD, asthma, and ACO and discusses the data supporting guideline recommendations for use of bronchodilators in COPD treatment in contrast to asthma or ACO.

摘要

COPD 在许多患者中经常被误诊和不当治疗。COPD 是一种与成人起病的哮喘不同的疾病;然而,一些 COPD 患者可能表现出几种气道疾病,被描述为哮喘-COPD 重叠(ACO)。支气管扩张剂和吸入皮质类固醇(ICS)在 COPD 和哮喘的标准维持治疗中都有一席之地;然而,使用建议却大相径庭。在 COPD 患者中,长效支气管扩张剂是有效的初始单药治疗,而 ICS 单药治疗则被推荐用于哮喘患者的初始治疗。临床医生需要对自己的诊断有信心,以确保给予正确的治疗,因为错误的治疗决策可能会给患者带来显著增加的安全风险。本综述强调了 COPD、哮喘和 ACO 在诊断和治疗方面的差异,并讨论了支持在 COPD 治疗中使用支气管扩张剂的指南建议的数据,与哮喘或 ACO 形成对比。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验